2DR Stock Chart & Stats
€51.50
€1.80(4.27%)
At close: 4:00 PM EDT
€51.50
€1.80(4.27%)
Day’s Range― - ―
52-Week Range€33.60 - €121.90
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€1.83B
Enterprise Value€999.46
Total Cash (Recent Filing)€320.68M
Total Debt (Recent Filing)€29.09M
Price to Earnings (P/E)15.6
Beta0.60
Next Earnings
Nov 09, 2026EPS Estimate
0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.66
Shares Outstanding28,910,376
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)3.47
Price to Sales (P/S)2.97
P/FCF Ratio34.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€52.49Price Target Upside1.93% Upside
Rating ConsensusHold
Number of Analyst Covering14
EPS Forecast (FY)1.03
Revenue Forecast (FY)€735.32M
Bulls Say, Bears Say
Bulls Say
Low Leverage And LiquidityAn exceptionally lightly leveraged balance sheet gives Inspire substantial flexibility to fund commercial initiatives, absorb reimbursement disruption, and invest without depending heavily on lenders. The $415 million cash and investment position also supports resilience through an uncertain operating period.
Strong Profitability And Cash GenerationHigh gross margins and restored net profitability indicate that the therapy model can generate meaningful earnings once revenue scales. Solid operating and free cash flow provide internal funding for patient access, education, and product expansion while reducing reliance on external capital.
Clinical Evidence Supports AdoptionPublished and presented clinical evidence supporting Inspire V can strengthen physician confidence and patient acceptance, helping differentiate the therapy from CPAP for appropriate patients. Better demonstrated outcomes may support durable adoption across trained centers and referral networks.
Bears Say
Revenue Growth Has WeakenedThe recent revenue contraction shows that demand conversion and sales execution are being affected despite the company’s established product position. Sustained weakness would reduce operating leverage, slow reinvestment, and make the path toward stronger margins more dependent on recovery in procedure volume.
Reimbursement And Coding UncertaintyCoding and reimbursement changes directly affect hospital, ASC, and physician economics, creating uneven incentives and delaying procedure decisions. Continued uncertainty around WISeR scope and regional modifier requirements could prolong access friction, complicate planning, and pressure revenue over coming quarters.
Cash Conversion Remains VolatileAlthough current cash generation is healthy, free cash flow has not consistently matched reported earnings and has shown meaningful historical swings. Uneven conversion can constrain the reliability of internally funded growth, particularly when reimbursement disruption or restructuring-related spending increases working-capital demands.
Inspire Medical Systems News
2DR FAQ
What was Inspire Medical Systems’s price range in the past 12 months?
Inspire Medical Systems lowest stock price was €33.60 and its highest was €121.90 in the past 12 months.
What is Inspire Medical Systems’s market cap?
Inspire Medical Systems’s market cap is €1.83B.
When is Inspire Medical Systems’s upcoming earnings report date?
Inspire Medical Systems’s upcoming earnings report date is Nov 09, 2026 which is in 52 days.
How were Inspire Medical Systems’s earnings last quarter?
Inspire Medical Systems released its earnings results on Aug 03, 2026. The company reported €0.121 earnings per share for the quarter, beating the consensus estimate of -€0.205 by €0.326.
Is Inspire Medical Systems overvalued?
According to Wall Street analysts Inspire Medical Systems’s price is currently Undervalued.
Does Inspire Medical Systems pay dividends?
Inspire Medical Systems does not currently pay dividends.
What is Inspire Medical Systems’s EPS estimate?
Inspire Medical Systems’s EPS estimate is 0.07.
How many shares outstanding does Inspire Medical Systems have?
Inspire Medical Systems has 28,910,376 shares outstanding.
What happened to Inspire Medical Systems’s price movement after its last earnings report?
Inspire Medical Systems reported an EPS of €0.121 in its last earnings report, beating expectations of -€0.205. Following the earnings report the stock price went up 20.495%.
Which hedge fund is a major shareholder of Inspire Medical Systems?
Currently, no hedge funds are holding shares in DE:2DR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inspire Medical Systems Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€52.49 (1.93% Upside)
€52.49 (1.93% Upside)
Blogger Sentiment
Bullish
DE:2DR Sentiment 90%
Sector Average 63%
Sector Average 63%
Insider Transactions
Sold Shares
Worth €49.4K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-9.07%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
15.43%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Inspire Medical Systems
Inspire Medical Systems, Inc. operates as a medical technology enterprise, concentrating on the development and commercialization of advanced, minimally intrusive therapies for patients diagnosed with obstructive sleep apnea (OSA) across both domestic U.S. and international markets. A cornerstone of its product portfolio is the Inspire system, an innovative neurostimulation solution that offers a safe and proven effective treatment for individuals experiencing moderate to severe forms of OSA. Additionally, the company is pioneering a novel, closed-loop technology designed to continuously track a patient's breathing patterns and administer mild stimulation to the hypoglossal nerve, thereby maintaining an open airway. Founded in 2007, Inspire Medical Systems maintains its corporate headquarters in Golden Valley, Minnesota.
2DR Company Deck
2DR Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a balanced picture: meaningful near-term headwinds from coding and reimbursement disruption depressed top-line growth (Q2 revenue down 7.6% and a full-year disruption impact estimated at $120M–$130M), drove elevated tax and restructuring items, and widened near-term guidance. Offsetting these challenges, management delivered profitability and positive operating cash flow ahead of expectations, possesses a strong cash position ($415M, no debt), announced Project Horizon to create $30M of reinvestment capacity, and highlighted strong clinical evidence and favorable proposed CMS facility reimbursement changes (+12% hospital, +15% ASC for 2027). Given the comparable weight of material negatives (revenue/headwinds, restructuring, reimbursement uncertainty) and material positives (cashflow, balance sheet, clinical momentum and planned reinvestment), the overall tone is balanced with a path to recovery but meaningful near-term uncertainty.View all DE:2DR earnings summaries2DR Revenue Breakdown
97.02% U.S.
2.98% Other
2DR Stock 12 Month Forecast
Average Price Target
€52.49
▲(1.93% Upside)